Výsledky vyhledávání - "Carlos Guillermo Romo"

Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities

Autor: Alfonso Quintás-Cardama, Aziz Nazha, Farhad Ravandi, Gautam Borthakur, Srdan Verstovsek, Hagop M. Kantarjian, Elias Jabbour, Jorge E. Cortes, Sherry Pierce, Marylou Cardenas-Turanzas, Carlos Guillermo Romo, Preetesh Jain, Susan O'Brien

Publikováno v: Blood. 121:4867-4874

Early responses to tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML)-chronic phase (CP) are associated with improved outcome. We analyzed the impact of such a response on outcomes among patients treated with 4 TKI modalities as fron

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::27b77d5cff37a7cdbd5e452241cfcb9b
https://doi.org/10.1182/blood-2013-03-490128

Zobrazit plný text záznamu

Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months

Autor: Alfonso Quintás-Cardama, Lynne V. Abruzzo, Raja Luthra, Hagop M. Kantarjian, Elias Jabbour, Jorge E. Cortes, Sherry Pierce, Carlos Guillermo Romo, Farhad Ravandi, Preetesh Jain, Aziz Nazha, Gautam Borthakur, Susan O'Brien

Publikováno v: Haematologica. 98:1686-1688

Response to tyrosine kinase inhibitors at three months is a predictor for long-term outcome in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors. We analyzed 456 newly diagnosed chronic myeloid leukemia patients treated with t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f773935928f70de464b9e5c59c79c97
https://doi.org/10.3324/haematol.2013.090282

Zobrazit plný text záznamu

Spontaneous remission of chemo-immunotherapy related, non-transplant Epstein–Barr virus-associated lymphoproliferative disorder in a patient with chronic lymphocytic leukemia

Autor: Mohamed Shamel Mohamed, Zeev Estrov, Carlos Guillermo Romo, Preetesh Jain, Sergej Konoplev, Ohad Benjamini

Publikováno v: Leukemia & Lymphoma. 54:2540-2542

A 75-year-old man presented with a 1-month history of rapidly progressive cervical lymphadenopathy, swallowing difficulty and B symptoms (fever, night sweats and weight loss). Review of outside hospital records showed that one year ago, patient under

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a2fb12a000a0b4aaa87763a411720c83
https://doi.org/10.3109/10428194.2013.773995

Zobrazit plný text záznamu

Plný text ve formátu HTML

Assessing need for palliative care services for children in Mexico

Autor: Marylou Cardenas-Turanzas, Carlos Guillermo Romo, Regina Okhuysen-Cawley, Horacio Tovalin-Ahumada

Publikováno v: Journal of palliative medicine. 18(2)

Pediatric palliative care increasingly became integrated into health care institutions worldwide over the last decade. However, in Mexico and other developing countries with large populations of children, little is known regarding the need for pallia

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf926118f2e87c0723beb0aa56115e89
https://pubmed.ncbi.nlm.nih.gov/25353338

Zobrazit plný text záznamu

Impact of the Type of BCR-ABL Fusion Transcripts on Response and Survival in Patients with Chronic Phase CML Treated with Four Frontline TKI Modalities

Autor: Farhad Ravandi, Zeev Estrov, Hagop M. Kantarjian, Susan O'Brien, Jorge E. Cortes, Koji Sasaki, Gautam Borthakur, Raja Luthra, Preetesh Jain, Carlos Guillermo Romo, Graciela M. Nogueras González, Tapan M. Kadia, Keyur P. Patel, Elias Jabbour

Publikováno v: Blood. 126:598-598

Introduction: Most commonly observed BCR-ABL transcripts in CML are b3a2 (e14a2) and b2a2 (e13a2). The significance of transcript type regarding r outcome after frontline therapy with different TKI is not well known. Methods: 481 pts with newly diagn

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7c8239d7785df17d028327bac3324eb8
https://doi.org/10.1182/blood.v126.23.598.598

Zobrazit plný text záznamu

Clinical activity of ponatinib in patients with chronic myeloid leukemia in chronic phase with e1a2 transcripts

Autor: Hanna Jean Khoury, Preetesh Jain, Hagop M. Kantarjian, Jorge E. Cortes, Carlos Guillermo Romo

Publikováno v: Haematologica. 98:e141-e142

The two major types of transcripts[1][1] of the BCR-ABL1 oncoprotein are b2a2 (e13a2) and b3a2 (e14a2). These transcripts are observed in over 95% of patients with chronic myeloid leukemia in chronic phase (CML-CP) at the time of initial presentation

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::256c32a79e15c6880c2c56b52bdcc2bb
https://doi.org/10.3324/haematol.2013.092882

Zobrazit plný text záznamu

BCR-ABL Fusion Transcripts In Patients With Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Experience With Ponatinib From MD Anderson Cancer Center

Autor: Preetesh Jain, Hagop M. Kantarjian, Carlos Guillermo Romo, Rajyalakshmi Luthra, Alfonso Quintas-Cardama, Elias Jabbour, Tapan M. Kadia, Gautam Borthakur, Marylou Cardenas-Turanzas, Dr PH, Sherry Pierce, Farhad Ravandi, Susan M. O'Brien, Jorge E. Cortes

Publikováno v: Blood. 122:2727-2727

Introduction The presence of the BCR-ABL fusion gene, resulting from the Philadelphia chromosome is the hallmark of CML. The most commonly observed transcripts in CML are b3a2 (e14a2) and b2a2 (e13a2). It is not known whether the transcript type may

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::63bd7e324e531d24c975ec4ae2a78f52
https://doi.org/10.1182/blood.v122.21.2727.2727

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání